Michael Prummer

Michael Prummer

Auto-generated profile, based on publicly available information

Michael Prummer

NEXUS Personalized Health Technologies, ETH Zürich, Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2015 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
CPChristoph Patsch
Christoph Patsch
LCLudivine Challet-Meylan
Ludivine Challet-Meylan
ETEva C. Thoma
Eva C. Thoma
EUEduard Urich
Eduard Urich
THTobias Heckel
Tobias Heckel
CCChad A. Cowan
Chad A. Cowan
The use of human pluripotent stem cells for in vitro disease modelling and clinical applications requires protocols that convert these cells into relevant adult cell types. Here, we report the rapid and efficient differentiation of human pluripotent stem cells into vascular endothelial and smooth muscle cells. We found that GSK3 inhibition and BMP4 treatment rapidly committed pluripotent cells to a mesodermal fate and subsequent exposure to VEGF-A or PDGF-BB resulted in the differentiation of either endothelial or vascular smooth muscle cells, respectively. Both protocols produced mature cells with efficiencies exceeding 80% within six days. On purification to 99% via surface markers, endothelial cells maintained their identity, as assessed by marker gene expression, and showed relevant in vitro and in vivo functionality. Global transcriptional and metabolomic analyses confirmed that the cells closely resembled their in vivo counterparts. Our results suggest that these cells could be used to faithfully model human disease.

1 March 1999 in Microscopy Research and Technique
Verified
Journal Article
Closed access
PDF file
APA. Pralle
A. Pralle
MPM. Prummer
M. Prummer
EFE.-L. Florin
E.-L. Florin
ESE.H.K. Stelzer
E.H.K. Stelzer
JHJ.K.H. Hörber
J.K.H. Hörber

1 November 2014 in Cell Reports
Verified
Journal Article
Open access
FDFaye M. Drawnel
Faye M. Drawnel
SBStefano Boccardo
Stefano Boccardo
MPMichael Prummer
Michael Prummer
FDFrédéric Delobel
Frédéric Delobel
AGAlexandra Graff
Alexandra Graff
RIRoberto Iacone
Roberto Iacone
Diabetic cardiomyopathy is a complication of type 2 diabetes, with known contributions of lifestyle and genetics. We develop environmentally and genetically driven in vitro models of the condition using human-induced-pluripotent-stem-cell-derived cardiomyocytes. First, we mimic diabetic clinical chemistry to induce a phenotypic surrogate of diabetic cardiomyopathy, observing structural and functional disarray. Next, we consider genetic effects by deriving cardiomyocytes from two diabetic patients with variable disease progression. The cardiomyopathic phenotype is recapitulated in the patient-specific cells basally, with a severity dependent on their original clinical status. These models are incorporated into successive levels of a screening platform, identifying drugs that preserve cardiomyocyte phenotype in vitro during diabetic stress. In this work, we present a patient-specific induced pluripotent stem cell (iPSC) model of a complex metabolic condition, showing the power of this technique for discovery and testing of therapeutic strategies for a disease with ever-increasing clinical significance.

11 August 2006 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
GGGopakumar Gopalakrishnan
Gopakumar Gopalakrishnan
CDChristophe Danelon
Christophe Danelon
PIPaulina Izewska
Paulina Izewska
MPMichael Prummer
Michael Prummer
PBPierre‐Yves Bolinger
Pierre‐Yves Bolinger
HVHorst Vogel
Horst Vogel

8 December 2014 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
AMAnnie Moisan
Annie Moisan
YLYoun-Kyoung Lee
Youn-Kyoung Lee
JZJitao David Zhang
Jitao David Zhang
CHCarolyn S. Hudak
Carolyn S. Hudak
CMClaas A. Meyer
Claas A. Meyer
CCChad A. Cowan
Chad A. Cowan
The rising incidence of obesity and related disorders such as diabetes and heart disease has focused considerable attention on the discovery of new therapeutics. One promising approach has been to increase the number or activity of brown-like adipocytes in white adipose depots, as this has been shown to prevent diet-induced obesity and reduce the incidence and severity of type 2 diabetes. Thus, the conversion of fat-storing cells into metabolically active thermogenic cells has become an appealing therapeutic strategy to combat obesity. Here, we report a screening platform for the identification of small molecules capable of promoting a white-to-brown metabolic conversion in human adipocytes. We identified two inhibitors of Janus kinase (JAK) activity with no precedent in adipose tissue biology that stably confer brown-like metabolic activity to white adipocytes. Importantly, these metabolically converted adipocytes exhibit elevated UCP1 expression and increased mitochondrial activity. We further found that repression of interferon signalling and activation of hedgehog signalling in JAK-inactivated adipocytes contributes to the metabolic conversion observed in these cells. Our findings highlight a previously unknown role for the JAK–STAT pathway in the control of adipocyte function and establish a platform to identify compounds for the treatment of obesity.

1 September 2011 in Cell Metabolism
Verified
Journal Article
Closed access
DEDaria Esterházy
Daria Esterházy
ISIna Stützer
Ina Stützer
HWHaiyan Wang
Haiyan Wang
MRMarkus P. Rechsteiner
Markus P. Rechsteiner
JBJeremy Beauchamp
Jeremy Beauchamp
MSMarkus Stoffel
Markus Stoffel